Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Werewolf Therapeutics, Inc. - Common Stock (NQ:HOWL)

0.6122 +0.0062 (+1.02%)
Streaming Delayed Price Updated: 4:00 PM EST, Feb 6, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 204,260
Open 0.6490
Bid (Size) 0.5934 (300)
Ask (Size) 0.6525 (6,300)
Prev. Close 0.6060
Today's Range 0.6000 - 0.6499
52wk Range 0.5301 - 2.380
Shares Outstanding 27,567,728
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
News headline image
Top movers in Thursday's session ↗
Stay up-to-date with the latest market trends one hour before the close of the markets on Thursday. Explore the top gainers and losers during today's session in our detailed report. 
Via Chartmill
News headline image
Keep an eye on the top gainers and losers in Thursday's session. ↗
Keep an eye on the top gainers and losers in Thursday's session, as they reflect the most notable price movements. 
Via Chartmill

Performance

YTD
-5.1%
-5.1%
1 Month
-4.7%
-4.7%
3 Month
-49.0%
-49.0%
6 Month
-48.1%
-48.1%
1 Year
-56.6%
-56.6%

More News

Read More
News headline image
There are notable gap-ups and gap-downs in today's session. ↗
Via Chartmill
One Patient's Complete Response to Investigational Cancer Therapy Sparks Hope
Via Brandpoint
News headline image
Werewolf Therapeutics Announces Pipeline and Business Updates
From Werewolf Therapeutics, Inc.
Via GlobeNewswire
News headline image
Werewolf Therapeutics Presents Data Expanding Its PREDATOR® Platform at the Society for Immunotherapy of Cancer’s (SITC) 40th Annual Meeting
From Werewolf Therapeutics, Inc.
Via GlobeNewswire
News headline image
12 Health Care Stocks Moving In Wednesday's Pre-Market Session ↗
Via Benzinga
News headline image
Werewolf Therapeutics Reports Third Quarter 2025 Financial Results and Provides Business Update
From Werewolf Therapeutics, Inc.
Via GlobeNewswire
News headline image
Werewolf Therapeutics Receives Fast Track Designation from the U.S. FDA for WTX-124, an Investigational Therapy for the Treatment of Cancer
From Werewolf Therapeutics, Inc.
Via GlobeNewswire
News headline image
Werewolf Therapeutics to Present Posters at the Society for Immunotherapy of Cancer’s (SITC) 40th Annual Meeting
From Werewolf Therapeutics, Inc.
Via GlobeNewswire
News headline image
12 Health Care Stocks Moving In Tuesday's Pre-Market Session ↗
Via Benzinga
News headline image
12 Health Care Stocks Moving In Monday's After-Market Session ↗
Via Benzinga
News headline image
Curious about the stocks that are showing activity after the closing bell on Monday? ↗
Via Chartmill
News headline image
Werewolf Therapeutics to Participate in the Upcoming H.C. Wainwright 27th Annual Global Investment Conference
From Werewolf Therapeutics, Inc.
Via GlobeNewswire
News headline image
Werewolf Reports No Revenue in Fiscal Q2 ↗
Via The Motley Fool
News headline image
Werewolf Therapeutics Reports Second Quarter 2025 Financial Results and Provides Business Update
From Werewolf Therapeutics, Inc.
Via GlobeNewswire
News headline image
Werewolf Therapeutics to Participate in the KidneyCAN 7th Annual Kidney Cancer Research Summit
From Werewolf Therapeutics, Inc.
Via GlobeNewswire
News headline image
Werewolf Therapeutics to Participate in the BIO International Convention
From Werewolf Therapeutics, Inc.
Via GlobeNewswire
News headline image
Werewolf Therapeutics to Participate in the Upcoming Jefferies Global Healthcare Conference
From Werewolf Therapeutics, Inc.
Via GlobeNewswire
News headline image
Top movers in Tuesday's after hours session ↗
Via Chartmill
News headline image
HonorHealth Research Institute patient with advanced skin cancer in remission for more than a year following clinical trial of Werewolf Therapeutics' investigational novel conditionally activated IL-2 pro-drug WTX-124
From Werewolf Therapeutics, Inc.
Via GlobeNewswire
News headline image
Werewolf Therapeutics to Participate in Hanson Wade’s 6th Annual Cytokine-Based Drug Development Summit
From Werewolf Therapeutics, Inc.
Via GlobeNewswire
News headline image
Werewolf Therapeutics Reports First Quarter 2025 Financial Results and Provides Business Update
From Werewolf Therapeutics, Inc.
Via GlobeNewswire
News headline image
Werewolf Therapeutics Presents New Preclinical Data Further Characterizing its IL-10 INDUKINE Molecule, WTX-921, for the Treatment of Inflammatory Bowel Disease (IBD) at AAI Annual Meeting
From Werewolf Therapeutics, Inc.
Via GlobeNewswire
News headline image
Werewolf Therapeutics to Participate in Upcoming Investor Conferences
From Werewolf Therapeutics, Inc.
Via GlobeNewswire

Frequently Asked Questions

Is Werewolf Therapeutics, Inc. - Common Stock publicly traded?
Yes, Werewolf Therapeutics, Inc. - Common Stock is publicly traded.
What exchange does Werewolf Therapeutics, Inc. - Common Stock trade on?
Werewolf Therapeutics, Inc. - Common Stock trades on the Nasdaq Stock Market
What is the ticker symbol for Werewolf Therapeutics, Inc. - Common Stock?
The ticker symbol for Werewolf Therapeutics, Inc. - Common Stock is HOWL on the Nasdaq Stock Market
What is the current price of Werewolf Therapeutics, Inc. - Common Stock?
The current price of Werewolf Therapeutics, Inc. - Common Stock is 0.6122
When was Werewolf Therapeutics, Inc. - Common Stock last traded?
The last trade of Werewolf Therapeutics, Inc. - Common Stock was at 02/06/26 04:00 PM ET
What is the market capitalization of Werewolf Therapeutics, Inc. - Common Stock?
The market capitalization of Werewolf Therapeutics, Inc. - Common Stock is 16.88M
How many shares of Werewolf Therapeutics, Inc. - Common Stock are outstanding?
Werewolf Therapeutics, Inc. - Common Stock has 17M shares outstanding.
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.